Publication:
Systemic treatment of renal cell cancer: A comprehensive review.

Simple item page
dc.contributor.authorSánchez-Gastaldo, Amparo
dc.contributor.authorKempf, Emmanuelle
dc.contributor.authorGonzález Del Alba, Aránzazu
dc.contributor.authorDuran, Ignacio
dc.date.accessioned2023-01-25T09:51:59Z
dc.date.available2023-01-25T09:51:59Z
dc.date.issued2017-09-01
dc.description.abstractKidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
dc.identifier.doi10.1016/j.ctrv.2017.08.010
dc.identifier.essn1532-1967
dc.identifier.pmid28898679
dc.identifier.unpaywallURLhttp://www.cancertreatmentreviews.com/article/S0305737217301421/pdf
dc.identifier.urihttp://hdl.handle.net/10668/11573
dc.journal.titleCancer treatment reviews
dc.journal.titleabbreviationCancer Treat Rev
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number77-89
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAngiogenesis
dc.subjectImmunotherapy
dc.subjectMonoclonal antibody
dc.subjectRenal cell cancer
dc.subjectTargeted therapy
dc.subjectTyrosine-kinase inhibitor
dc.subjectmTOR inhibitor
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshKidney Neoplasms
dc.subject.meshMolecular Targeted Therapy
dc.titleSystemic treatment of renal cell cancer: A comprehensive review.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number60
dspace.entity.typePublication

Files

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía